NCT04981613View on ClinicalTrials.gov

Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

August 28, 2024

Study Completion Date

August 28, 2024

Conditions
Diabetic Nephropathy
Interventions
DRUG

Kunxian capsule

Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks

Trial Locations (1)

710061

First Affiliated Hospital of Xian Jiaotong University, Xi'an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT04981613 - Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter